Home » Stocks » AXDX

Accelerate Diagnostics, Inc. (AXDX)

Stock Price: $10.16 USD 0.15 (1.50%)
Updated Mar 1, 2021 4:00 PM EST - Market closed
After-hours: $10.04 -0.12 (-1.18%) Mar 1, 4:52 PM
Market Cap 609.19M
Revenue (ttm) 11.53M
Net Income (ttm) -80.63M
Shares Out 56.56M
EPS (ttm) -1.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $10.16
Previous Close $10.01
Change ($) 0.15
Change (%) 1.50%
Day's Open 10.12
Day's Range 9.99 - 10.57
Day's Volume 199,039
52-Week Range 4.53 - 19.11

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 month ago

TUCSON, Ariz., Jan. 12, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the fourth quarter and full year ending December 31, ...

Seeking Alpha - 3 months ago

Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 3 months ago

TUCSON, Ariz., Nov. 5, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2020. "We achieved solid rev...

Zacks Investment Research - 4 months ago

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 6 months ago

TUCSON, Ariz., Aug. 24, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc.

The Motley Fool - 6 months ago

This new testing platform will speed up health checks by determining whether asymptomatic people have COVID-19 antibodies in 30 minutes.

PRNewsWire - 6 months ago

TUCSON, Ariz., Aug. 18, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc.

Seeking Alpha - 6 months ago

Accelerate Diagnostics (AXDX) CEO Jack Phillips on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 6 months ago

TUCSON, Ariz., Aug. 6, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc.

Zacks Investment Research - 7 months ago

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 9 months ago

Accelerate Diagnostics (AXDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the ne...

Zacks Investment Research - 9 months ago

Accelerate Diagnostics (AXDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Seeking Alpha - 9 months ago

Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

Accelerate Diagnostics (AXDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

InvestorPlace - 10 months ago

Market watchers are looking to the insiders, hoping insights from their activity can steer them towards returns.

Other stocks mentioned: CDLX, GIII, NGM, OPK
Seeking Alpha - 10 months ago

Daily Insider Ratings Round Up 4/1/20

Other stocks mentioned: CWEN, FPH, IFF, MGM, MYOV, NCMI, XPO
Seeking Alpha - 1 year ago

Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 1 year ago

Two of the sector's biggest winners of the past 10 years are still flying under the radar. Which looks like the better buy today?

Other stocks mentioned: SLP
The Motley Fool - 1 year ago

Which biotech was a 37-bagger?

Other stocks mentioned: ABMD, ACAD, DXCM, EXAS, JAZZ, NBIX, NEO, RGEN, SLP
Seeking Alpha - 1 year ago

Accelerate Diagnostics, Inc. (AXDX) CEO Larry Mehren on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 5.13% and -27.97%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead fo...

Zacks Investment Research - 1 year ago

Accelerate Diagnostics (AXDX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Seeking Alpha - 1 year ago

Finally, reaching a positive inflection point for devices under contract.

Seeking Alpha - 1 year ago

Accelerate Diagnostics' (AXDX) CEO Larry Mehren on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 5.00% and -33.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the...

Seeking Alpha - 1 year ago

Accelerate Diagnostics, Inc. (AXDX) CEO Lawrence Mehren on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 6.98% and -17.57%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for th...

Zacks Investment Research - 1 year ago

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About AXDX

Accelerate Diagnostics, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnosti... [Read more...]

Industry
Diagnostics & Research
IPO Date
Nov 18, 1996
CEO
John Phillips
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
AXDX
Full Company Profile

Financial Performance

In 2019, AXDX's revenue was $9.30 million, an increase of 63.97% compared to the previous year's $5.67 million. Losses were -$84.31 million, -4.55% less than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for AXDX stock is "Buy." The 12-month stock price forecast is 12.33, which is an increase of 21.36% from the latest price.

Price Target
$12.33
(21.36% upside)
Analyst Consensus: Buy